WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study

General Inclusion Criteria: * Age ≥ 18 years and ≤ 75 years. * Life expectancy ≥ 16 weeks (4 months). * World Health Organisation (WHO) performance status of 0-2 * HLA A\*0201 positive * Completed previous course of chemotherapy ≥ 4 weeks prior to commencing the initial phase of the trial (leucapheresis for collection of patient PBMC). * Peripheral blood total lymphocyte count \> 0.5x109/L. * Informed consent in writing and ability to co-operate with treatment and follow up. * Willing, able and available for collection of PBMC/ T cells by leucapheresis. * Hepatitis B and C, HTLV-1, Syphilis, HIV negative. * Free from serious concurrent illness. * Female patients of child-bearing age must have a negative pregnancy test and agree to use reliable contraceptive methods for the duration of the therapy and for 6 months afterwards. * Male patients must agree to use appropriate medically approved contraception during the trial and for six months afterwards. * Haematological and Biochemical Indices: * Haemoglobin (Hb) ≥ 7.0 g/dl; neutrophils ≥ 0.2 x 109/L; total lymphocytes \> 0.5 x 109/L; platelets (Plts) ≥ 40 x 109/L * serum bilirubin, Alanine amino-transferase (ALT) and/or aspartate amino transferase (AST) \< 3 x upper normal limit * calculated creatinine clearance ≥ 30 ml/min (uncorrected value) or isotope clearance measurement ≥ 30ml/min Further disease specific inclusion criteria are detailed in Protocol Exclusion Criteria: * Age \< 18 years or \> 75 years. * Patients should not receive concurrent systemic corticosteroids whilst on the study. * Within three months of having received fludarabine (at time of leucapheresis). * Major thoracic and/or abdominal surgery in the preceding three to four weeks from which the patient has not yet recovered. * Patients who are high medical risks because of non-malignant systemic disease, as well as those with active uncontrolled infection. * Patients with any other condition, which in the Investigator's opinion would not make the patient a good candidate for the clinical trial. * Patients known to be serologically positive for Hepatitis B, C, HTLV-1 Syphilis or HIV. * Concurrent congestive heart failure or prior history of New York Heart Association (NYHA) class III/ IV cardiac disease * Positive pregnancy test or reluctance to use contraception. * Pregnant and lactating women are excluded. * History of Severe Allergy.